Chris House, Senior Vice President of Product Management and Development at NantHealth®, a healthcare company, discusses NaviNet®, a payer-provider collaboration platform by NantHealth. He also talks about how many health tech companies jumped in to help with COVID-19 initiatives. For instance, during the month of May, NantHealth’s NaviNet® AllPayer platform was free to providers.
Dr. Andrew Blumenfeld, MD, director of the Headache Center of Southern California discusses the often misunderstood condition of migraine, how the disease is typically managed, and the latest development in treatment options. VYEPTI™ (eptinezumab-jjmr) is a prescription medicine used for the preventive treatment of migraine in adults.
Dr. Laurie Keefer, PhD, a psychologist with Mount Sinai Hospital’s IBD Center in New York City who specializes in the psychosocial care of patients with chronic digestive diseases, most notably Crohn’s and ulcerative colitis (UC) and Allyson a patient living with UC discuss UC, living with UC and the emotional impact of UC on daily living especially now in the COVID-19 pandemic.
Bruce Boise, who worked in the pharmaceutical industry for over 20 years tells his story and discusses his new book “Cold Comfort: One man’s struggle to stop the illegal marketing of powerful opioid drugs and save lives”.
Dr. Andrew Krivoshik, SVP, and Oncology Therapeutic Area Head at Astellas Pharma US discusses the overall survival findings from the Phase 3 PROSPER trial in men with non-metastatic castration-resistant prostate cancer (nmCRPC) that was published in the online “New England Journal of Medicine” (NEJM) and also presented during the 2020 American Society of Clinical Oncology (ASCO20) Annual Meeting (Abstract #5515).
Dr. Ayman Al-Hendy, MD, discusses the recent FDA approval of AbbVie’s ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), a non-surgical, oral medication option, for premenopausal women to manage heavy bleeding due to uterine fibroids.
Lane Conger Maples, VP of Client Experience at Bridge Connector, a company offering interoperability and integration solutions discusses the current state of interoperability and healthcare information technology (HIT) during these unprecedented times brought on by the pandemic. She talks about that despite the financial strains happening across the healthcare industry due to COVID-19, interest and investments in integration technology has remained a priority for healthcare organizations.
Dr. Karim Richard Masri, a Rheumatologist at the Bon Secours Rheumatology center in Richmond, VA discusses new data released by Horizon Therapeutics at the Annual European Congress of Rheumatology (EULAR 2020) that shows the benefit of combining immunomodulators with KRYSTEXXA® (pegloticase injection) to help more people with uncontrolled gout achieve complete and durable responses. Other data shared at EULAR addressed the rate of amputation reinforcing the systemic and potentially devastating impact of uncontrolled gout. Dr. Masri also discusses details for prescribers on how to ensure patients are supported during COVID-19.
Dr. W. Michael Korn, Chief Medical Officer at Caris Life Sciences®, discusses the data presentation from the American Society of Clinical Oncology, (ASCO20) Virtual Scientific Program, Abstract 4629/Poster 237: Enrichment of alterations in targetable molecular pathways are enriched in KRAS wild-type (WT) pancreatic cancer (PC).
Dr. Chadi Nabhan, Chairman of Precision Oncology Alliance™ at Caris Life Sciences® and Dr. Stephen Liu, an oncologist with Medstar Health and an investigator on this study discuss the data presentation from the American Society of Clinical Oncology, (ASCO20) Virtual Scientific Program, Abstract 9544/Poster 310: Characterization of KRAS mutations in non-small cell lung cancer (NSCLC).